Quick access to up-to-date company information.
FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery
Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation’s Corporate Equality Index
Boehringer Ingelheim named one of the most innovative companies worldwide
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877